Steven A Rosenberg Selected Research

Cell- and Tissue-Based Therapy (Cell Therapy)

11/2019	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy.
1/2019	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
11/2018	T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.
6/2018	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
1/2017	A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
1/2016	Adoptive T-Cell Therapy for Cancer.
4/2015	Adoptive cell transfer as personalized immunotherapy for human cancer.
3/2015	A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
1/2015	Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.
5/2014	Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven A Rosenberg Research Topics

Disease

279	Neoplasms (Cancer) 01/2022 - 01/2002
180	Melanoma (Melanoma, Malignant) 01/2022 - 01/2002
22	Neoplasm Metastasis (Metastasis) 10/2019 - 05/2002
14	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 01/2002
12	Testicular Neoplasms (Testicular Cancer) 11/2020 - 04/2005
10	Kidney Neoplasms (Kidney Cancer) 06/2014 - 05/2002
7	Experimental Melanoma 06/2013 - 08/2004
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 10/2010
6	Brain Neoplasms (Brain Tumor) 06/2018 - 01/2002
5	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 12/2008
5	Lymphoma (Lymphomas) 01/2020 - 11/2010
5	Ovarian Neoplasms (Ovarian Cancer) 11/2019 - 05/2003
5	Adenocarcinoma 01/2019 - 01/2009
5	Leukemia 01/2019 - 09/2009
5	Sarcoma (Soft Tissue Sarcoma) 03/2015 - 03/2011
4	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2014
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 11/2020 - 09/2013
4	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2003
4	Lymphopenia (Lymphocytopenia) 01/2017 - 05/2002
4	Thrombocytopenia (Thrombopenia) 01/2017 - 01/2002
4	Synovial Sarcoma (Synovioma) 01/2016 - 08/2011
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2019 - 05/2015
3	Carcinoma (Carcinomatosis) 01/2019 - 02/2003
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2017 - 05/2003
3	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2016 - 12/2008
3	Colorectal Neoplasms (Colorectal Cancer) 03/2011 - 10/2003
3	Fowlpox 10/2009 - 08/2003
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 02/2015
2	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 04/2016
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019 - 01/2018
2	Disease Progression 01/2017 - 12/2010

Drug/Important Bio-Agent (IBA)

102	AntigensIBA 01/2022 - 01/2002
58	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 02/2004
58	Interleukin-2 (IL2)IBA 10/2021 - 01/2002
42	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 05/2002
39	Peptides (Polypeptides)IBA 01/2021 - 01/2002
32	Chimeric Antigen ReceptorsIBA 01/2020 - 09/2009
30	CytokinesIBA 01/2020 - 05/2002
27	EpitopesIBA 01/2022 - 05/2002
27	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
17	HLA-A*02:01 antigenIBA 01/2019 - 05/2002
16	VaccinesIBA 11/2020 - 06/2002
12	Differentiation AntigensIBA 11/2020 - 05/2002
10	InterleukinsIBA 01/2018 - 08/2003
9	Biomarkers (Surrogate Marker)IBA 11/2020 - 05/2003
9	Interleukin-15 (Interleukin 15)IBA 01/2018 - 02/2004
9	AutoantigensIBA 05/2017 - 09/2002
8	Interleukin-12 (IL 12)IBA 01/2020 - 09/2010
8	Monophenol Monooxygenase (Tyrosinase)IBA 05/2014 - 01/2002
7	HLA Antigens (Human Leukocyte Antigens)IBA 11/2018 - 05/2003
7	IpilimumabIBA 10/2013 - 05/2006
7	Melanoma-Specific AntigensIBA 10/2010 - 01/2002
7	CTLA-4 AntigenIBA 07/2008 - 07/2003
6	HLA-A Antigens (HLA-A)IBA 01/2022 - 05/2008
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 07/2003
6	fludarabineIBA 05/2011 - 05/2002
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2011 - 05/2002
5	Interferon-gamma (Interferon, gamma)IBA 01/2020 - 03/2009
5	LigandsIBA 01/2019 - 08/2003
5	gp100 Melanoma AntigenIBA 10/2009 - 08/2003
4	HLA-C Antigens (HLA-C)IBA 01/2022 - 11/2012
4	InterferonsIBA 01/2021 - 11/2010
4	RNA (Ribonucleic Acid)IBA 05/2017 - 04/2005
4	Complementary DNA (cDNA)IBA 04/2016 - 07/2002
4	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 05/2003
4	Glycoproteins (Glycoprotein)IBA 12/2014 - 09/2003
4	SteroidsIBA 10/2012 - 05/2006
4	incomplete Freund's adjuvantIBA 06/2011 - 05/2004
4	Monoclonal AntibodiesIBA 04/2010 - 11/2004
4	Cancer VaccinesIBA 11/2006 - 05/2003
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2006
3	epidermal growth factor receptor VIIIIBA 01/2019 - 10/2012
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 10/2012
3	Immunodominant EpitopesIBA 06/2013 - 05/2003
3	interferon tauIBA 06/2013 - 12/2008
3	SuspensionsIBA 10/2012 - 12/2008
3	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2012 - 07/2002
3	Small Interfering RNA (siRNA)IBA 09/2011 - 10/2009
3	Interleukin-7 (Interleukin 7)IBA 08/2011 - 01/2005
3	Protein Subunit VaccinesIBA 06/2011 - 01/2004
3	Therapeutic UsesIBA 09/2010 - 05/2003
3	Angiogenesis InhibitorsIBA 08/2010 - 05/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 05/2002
2	Cysteine (L-Cysteine)FDA Link 01/2020 - 12/2018
2	PlatinumIBA 10/2019 - 05/2015
2	Mutant Proteins (Protein, Mutant)IBA 01/2019 - 01/2018
2	DisulfidesIBA 12/2018 - 06/2010
2	ElementsIBA 11/2018 - 03/2009
2	HLA-DPB1 antigen (HLA DPB1)IBA 10/2017 - 01/2016
2	Immunoglobulins (Immunoglobulin)IBA 08/2017 - 05/2014
2	Carrier Proteins (Binding Protein)IBA 08/2017 - 07/2010
2	VemurafenibIBA 01/2017 - 10/2013

Therapy/Procedure

124	Therapeutics 01/2022 - 01/2002
124	Immunotherapy 01/2022 - 01/2002
30	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2019 - 04/2008
26	Drug Therapy (Chemotherapy) 06/2017 - 01/2002
7	Aftercare (After-Treatment) 10/2019 - 05/2009
3	Metastasectomy 01/2017 - 08/2004
3	Intravenous Administration 09/2003 - 01/2002